Stock Analysis, Dividends, Split History

GLBL / TerraForm Global, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.08
Volume371,800.00
Market Cap ($M)878.95
Enterprise Value ($M)1,760.54
Book Value ($M)658.52
Book Value / Share3.80
Price / Book1.33
NCAV ($M)-453.03
NCAV / Share-2.62
Price / NCAV-1.94
Share Statistics
Common Shares Outstanding 0
Shares Outstanding 174,596,735
Preferred Stock Shares Outstanding 0
Common Shares Outstanding2 112,952,170
Common Shares Outstanding3 61,343,054
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.04
Return on Assets (ROA)-0.03
Return on Equity (ROE)-0.11
Balance Sheet (mrq) ($M)
Assets2,429.24
Liabilities1,341.39
Quick Ration/a
Current Ratio1.74
Income Statement (mra) ($M)
Sales Revenue Net214,317,000.00
Operating Income28.46
Net Income-78.50
Earnings Per Share Basic Distributed0.27
Earnings Per Share Diluted Distributed0.27
Earnings Per Share Basic Undistributed-0.74
Earnings Per Share Diluted Undistributed-0.74
Earnings Per Share Basic And Diluted-0.47
Cash Flow Statement (mra) ($M)
Cash From Operations-14.24
Cash from Investing-37.25
Cash from Financing-37.25
Identifiers and Descriptors
CUSIP88104M101
Central Index Key (CIK)1620702
Related CUSIPS
88104M901 88104M951

Split History

Stock splits are used by TerraForm Global, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Brookfield Renewable Partners: Mid-Year Check-Up Passed, Buy For 6.4% Yield

2018-08-09 seekingalpha
After hitting a low point in 2016, the company appears to be back on track with strong revenue, adjusted consolidated EBITDA and FFO growth. (3-0)

Brookfield Renewable Partners (BEP) CEO Sachin Shah on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Good morning. My name is Carole and I will be your operator today. At this time, I would like to welcome everyone to the Brookfield Renewable Partners’ Second Quarter 2018 Earnings Call and Webcast. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, we will have a question-and-answer session. [Operator Instructions] (2-0)

2 Low-Risk, Recession-Resistant, High-Yield Stocks Worth Buying Today

2018-07-25 seekingalpha
That's thanks to their recession-resistant business models which allow slow but steady dividend growth through all economic conditions. (5-0)

A Primer On Brookfield Asset Management

2018-07-09 seekingalpha
Brookfield (BAM), an under-the-radar company, is one of the largest alternative asset managers in the world. (9-2)

Brookfield to sharpen focus on renewable energy sector in India

2018-06-28 livemint
Mumbai: Canada-based Brookfield Asset Management Inc. is looking to increase its focus on renewable energy in India, said two people aware of the firm’s plans, on the condition of anonymity. The asset manager has so far been focussing largely on the real estate and roads segment. (11-0)

CUSIP: 88104M101